ISO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ISO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. IsoPlexis's annualized net income for the quarter that ended in Dec. 2022 was $-132.85 Mil. IsoPlexis's average shareholder tangible equity for the quarter that ended in Dec. 2022 was $37.39 Mil. Therefore, IsoPlexis's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2022 was -355.28%.
The historical rank and industry rank for IsoPlexis's Return-on-Tangible-Equity or its related term are showing as below:
During the past 4 years, IsoPlexis's highest Return-on-Tangible-Equity was -37.32%. The lowest was -148.58%. And the median was -58.48%.
The historical data trend for IsoPlexis's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IsoPlexis Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Return-on-Tangible-Equity | -39.94 | -37.32 | -77.02 | -148.58 |
IsoPlexis Quarterly Data | |||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Return-on-Tangible-Equity | Get a 7-Day Free Trial | -137.18 | -106.79 | -124.87 | -119.60 | -355.28 |
For the Medical Devices subindustry, IsoPlexis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where IsoPlexis's Return-on-Tangible-Equity falls into.
IsoPlexis's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets ) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -105.997 | / | ( (121.237 | + | 21.443 ) | / 2 ) | |
= | -105.997 | / | 71.34 | ||||
= | -148.58 % |
IsoPlexis's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2022 is calculated as
Return-on-Tangible-Equity | = | Net Income | / | ( (Total Tangible Equity | + | Total Tangible Equity) | / count ) |
(Q: Dec. 2022 ) | (Q: Sep. 2022 ) | (Q: Dec. 2022 ) | |||||
= | Net Income | / | ( (Total Stockholders Equity - Intangible Assets | + | Total Stockholders Equity - Intangible Assets) | / count ) | |
(Q: Dec. 2022 ) | (Q: Sep. 2022 ) | (Q: Dec. 2022 ) | |||||
= | -132.848 | / | ( (53.343 | + | 21.443) | / 2 ) | |
= | -132.848 | / | 37.393 | ||||
= | -355.28 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.
IsoPlexis (NAS:ISO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thank you for viewing the detailed overview of IsoPlexis's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Nachum Shamir | director | 12212 TECHNOLOGY BLVD, AUSTIN TX 78727 |
John Strahley | officer: Chief Financial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Sean Mackay | director, officer: Chief Executive Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rew Richard W. Ii | officer: SVP, GC & Secretary | 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735 |
James R Heath | director | C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405 |
Michael Egholm | director | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
Siddhartha Kadia | director | 7475 LUSK BOULEVARD, SAN DIEGO CA 92121 |
Jason W. Myers | director | C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301 |
John G. Conley | director | 396 GREAT MEADOWS RD, CONCORD MA 01742-1803 |
Gregory P. Ho | director, 10 percent owner | C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022 |
Peter Siesel | officer: Chief Commercial Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Jing Zhou | officer: Chief Scientific Officer | 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405 |
Rajesh T. Khakhar | officer: VP, Finance | 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405 |
Northpond Capital Gp, Llc | 10 percent owner | 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By PRNewswire PRNewswire • 12-22-2022
By GuruFocusNews GuruFocusNews • 02-02-2022
By PurpleRose PurpleRose • 07-21-2022
By GuruFocusNews GuruFocusNews • 02-11-2022
By GuruFocusNews GuruFocusNews • 02-10-2022
By Ds*** Ds*** • 08-31-2022
By Business Wire Business Wire • 12-21-2022
By GuruFocusNews GuruFocusNews • 04-08-2022
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.